Spero Therapeutics (SPRO) announced the appointment of Esther Rajavelu as Chief Financial Officer, CFO, and Chief Business Officer, CBO. Rajavelu will succeed Stephen DiPalma, who has served as the company’s Interim CFO since August 1, 2023. Most recently, Rajavelu served as the CFO at Fulcrum Therapeutics (FULC)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRO:
- Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics management to meet with Truist
- Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference
- Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
